• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pathological ventricular remodeling: therapies: part 2 of 2.

作者信息

Xie Min, Burchfield Jana S, Hill Joseph A

机构信息

Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

出版信息

Circulation. 2013 Aug 27;128(9):1021-30. doi: 10.1161/CIRCULATIONAHA.113.001879.

DOI:10.1161/CIRCULATIONAHA.113.001879
PMID:23979628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3829603/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d3/3829603/83071243a908/nihms512424f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d3/3829603/83071243a908/nihms512424f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d3/3829603/83071243a908/nihms512424f1.jpg

相似文献

1
Pathological ventricular remodeling: therapies: part 2 of 2.病理性心室重塑：治疗方法：第2部分，共2部分
Circulation. 2013 Aug 27;128(9):1021-30. doi: 10.1161/CIRCULATIONAHA.113.001879.
2
Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.在预防心力衰竭猝死方面，神经激素拮抗剂优于植入式心脏复律除颤器。
JACC Heart Fail. 2019 Oct;7(10):902-906. doi: 10.1016/j.jchf.2019.05.013. Epub 2019 Sep 11.
3
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.射血分数降低的新诊断心力衰竭患者植入植入式心脏复律除颤器前的等待期：一个机会之窗。
Circ Heart Fail. 2017 Nov;10(11). doi: 10.1161/CIRCHEARTFAILURE.117.004478.
4
[Treatment of chronic systolic heart failure].[慢性收缩性心力衰竭的治疗]
Dtsch Med Wochenschr. 2013 Aug;138(31-32):1556. doi: 10.1055/s-0032-1330162. Epub 2013 Jul 24.
5
Heart failure medications prescribed at discharge for patients with left ventricular assist devices.左心室辅助装置患者出院时开具的心力衰竭药物。
Am Heart J. 2016 Sep;179:99-106. doi: 10.1016/j.ahj.2016.06.011. Epub 2016 Jun 23.
6
[Programs for continuing medical education: B session; 1. The pathophysiology of heart failure--is it the disease of the heart?].[继续医学教育项目：B组；1. 心力衰竭的病理生理学——它是心脏疾病吗？]
Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):681-6. doi: 10.2169/naika.103.681.
7
Myocardial recovery and the failing heart: medical, device and mechanical methods.心肌恢复和衰竭心脏：医学、器械和机械方法。
Ann Glob Health. 2014 Jan-Feb;80(1):55-60. doi: 10.1016/j.aogh.2013.12.006. Epub 2013 Dec 25.
8
MY APPROACH to treating heart failure with reduced ejection fraction.我治疗射血分数降低的心力衰竭的方法。
Trends Cardiovasc Med. 2014 Nov;24(8):367-8. doi: 10.1016/j.tcm.2014.06.008. Epub 2014 Aug 19.
9
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.植入式心脏除颤器仍是预防心力衰竭患者心源性猝死的有效疗法。
JACC Heart Fail. 2019 Oct;7(10):907-910. doi: 10.1016/j.jchf.2019.08.001. Epub 2019 Sep 11.
10
The treatment of chronic heart failure due to left ventricular systolic dysfunction.左心室收缩功能障碍所致慢性心力衰竭的治疗
Clin Med (Lond). 2004 Jan-Feb;4(1):18-22. doi: 10.7861/clinmedicine.4-1-18.

引用本文的文献

1
The Proteomic Landscape of the Coronary Accessible Heart Cell Surfaceome.冠状动脉可及的心脏细胞表面蛋白质组学图谱
Proteomics. 2025 Apr;25(7):e202400320. doi: 10.1002/pmic.202400320. Epub 2025 Jan 10.
2
Mst1/Hippo signaling pathway drives isoproterenol-induced inflammatory heart remodeling.Mst1/Hippo 信号通路驱动异丙肾上腺素诱导的炎症性心脏重构。
Int J Med Sci. 2024 Jul 1;21(9):1718-1729. doi: 10.7150/ijms.95850. eCollection 2024.
3
Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T.利用分子机制实现肌钙蛋白T突变所致扩张型心肌病的精准医学
bioRxiv. 2024 Apr 9:2024.04.05.588306. doi: 10.1101/2024.04.05.588306.
4
Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy.基质细胞-SLIT3/心肌细胞-ROBO1 轴调控压力超负荷诱导的心肌肥厚。
Circ Res. 2024 Mar 29;134(7):913-930. doi: 10.1161/CIRCRESAHA.122.321292. Epub 2024 Feb 27.
5
Fibroblasts in heart scar tissue directly regulate cardiac excitability and arrhythmogenesis.心脏疤痕组织中的成纤维细胞可直接调节心脏的兴奋性和心律失常发生。
Science. 2023 Sep 29;381(6665):1480-1487. doi: 10.1126/science.adh9925. Epub 2023 Sep 28.
6
Transcription factor EB (TFEB) improves ventricular remodeling after myocardial infarction by inhibiting Wnt/-catenin signaling pathway.转录因子 EB（TFEB）通过抑制 Wnt/-连环蛋白信号通路改善心肌梗死后的心室重构。
PeerJ. 2023 Aug 18;11:e15841. doi: 10.7717/peerj.15841. eCollection 2023.
7
Electrical Stimulation Increases the Secretion of Cardioprotective Extracellular Vesicles from Cardiac Mesenchymal Stem Cells.电刺激增加心脏间充质干细胞分泌心脏保护细胞外囊泡。
Cells. 2023 Mar 11;12(6):875. doi: 10.3390/cells12060875.
8
Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis.双重遗传示踪揭示了一种独特的成纤维细胞亚群，可调节心脏纤维化。
Nat Genet. 2023 Apr;55(4):665-678. doi: 10.1038/s41588-023-01337-7. Epub 2023 Mar 23.
9
Role of Nutrients and Foods in Attenuation of Cardiac Remodeling through Oxidative Stress Pathways.营养素和食物通过氧化应激途径在减轻心脏重构中的作用。
Antioxidants (Basel). 2022 Oct 20;11(10):2064. doi: 10.3390/antiox11102064.
10
The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding.SGLT2i 达格列净可降低 RV 质量，而不依赖于肺动脉带引起的 RV 压力变化。
Cardiovasc Drugs Ther. 2024 Feb;38(1):57-68. doi: 10.1007/s10557-022-07377-1. Epub 2022 Sep 29.

本文引用的文献

1
Pathological ventricular remodeling: mechanisms: part 1 of 2.病理性心室重构：机制：第 1 部分，共 2 部分。
Circulation. 2013 Jul 23;128(4):388-400. doi: 10.1161/CIRCULATIONAHA.113.001878.
2
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.磷酸二酯酶-5 抑制剂对射血分数保留心力衰竭患者运动能力和临床状态的影响：一项随机临床试验。
JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.
3
Heart failure with preserved ejection fraction: current understanding and emerging concepts.射血分数保留型心力衰竭：现有认识与新兴概念。
Curr Opin Cardiol. 2013 Mar;28(2):187-96. doi: 10.1097/HCO.0b013e32835c5492.
4
Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction.预测心力衰竭新发病例的因素：射血分数保留与降低心力衰竭的差异。
Circ Heart Fail. 2013 Mar;6(2):279-86. doi: 10.1161/CIRCHEARTFAILURE.112.972828. Epub 2012 Dec 27.
5
Diabetic cardiomyopathy and metabolic remodeling of the heart.糖尿病性心肌病与心脏的代谢重构。
Life Sci. 2013 Mar 28;92(11):609-15. doi: 10.1016/j.lfs.2012.10.011. Epub 2012 Oct 30.
6
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.经心内膜注射异体与自体骨髓间充质干细胞治疗缺血性心肌病的比较：POSEIDON 随机试验。
JAMA. 2012 Dec 12;308(22):2369-79. doi: 10.1001/jama.2012.25321.
7
Communication in the heart: the role of the innate immune system in coordinating cellular responses to ischemic injury.心脏中的通讯：固有免疫系统在协调细胞对缺血性损伤反应中的作用。
J Cardiovasc Transl Res. 2012 Dec;5(6):827-36. doi: 10.1007/s12265-012-9410-7. Epub 2012 Oct 5.
8
Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.贝叶斯适应性临床试验设计在急性心力衰竭综合征中的应用：超越大型试验。
Am Heart J. 2012 Aug;164(2):138-45. doi: 10.1016/j.ahj.2011.11.023. Epub 2012 Jul 9.
9
Heart repair by reprogramming non-myocytes with cardiac transcription factors.心脏转录因子对非心肌细胞的重编程实现心脏修复。
Nature. 2012 May 13;485(7400):599-604. doi: 10.1038/nature11139.
10
In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes.在体重编程鼠心肌成纤维细胞为诱导性心肌细胞。
Nature. 2012 May 31;485(7400):593-8. doi: 10.1038/nature11044.